• Home
  • Store
    • Total Access Subscriptions
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Institutional Site Licenses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • Toolkit
  • FAQs
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Access Purchased Content
Home » Fact Sheet

Articles Tagged with ''Fact Sheet''

Patient Sheet

Buprenorphine (Suboxone, Subutex) Fact Sheet for Patients

January 1, 2026
Daniel Carlat, MD and Talia Puzantian, PharmD, BCPP

Dr. Puzantian and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Brexpiprazole is used to treat certain mental/mood disorders such as schizophrenia, major depressive disorder, and dementia-associated agitation in patients with Alzheimer’s disease.



Read More
Patient Sheet

Brexpiprazole (Rexulti) Fact Sheet for Patients

January 1, 2026
Daniel Carlat, MD and Talia Puzantian, PharmD, BCPP

Dr. Puzantian and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Brexpiprazole is used to treat certain mental/mood disorders such as schizophrenia, major depressive disorder, and dementia-associated agitation in patients with Alzheimer’s disease.



Read More
Fact Sheet

Asenapine (Saphris, Secuado) Fact Sheet [G] for General Psychiatry

January 1, 2026
Daniel Carlat, MD and Talia Puzantian, PharmD, BCPP

Dr. Carlat and Dr. Puzantian have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Asenapine’s unique advantage is its availability in both sublingual and transdermal patch formulations, making it useful for patients who cannot or prefer not to swallow pills.


Read More
Fact Sheet

Varenicline (Chantix) Fact Sheet

January 1, 2026
Daniel Carlat, MD and Talia Puzantian, PharmD, BCPP

Dr. Puzantian and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Varenicline is the most effective tobacco cessation medication.




Read More
Fact Sheet

Nicotine Patch (Nicoderm CQ, others) Fact Sheet

January 1, 2026
Daniel Carlat, MD and Talia Puzantian, PharmD, BCPP

Dr. Puzantian and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Nicotine patches are a first-line intervention in patients who are able to quit smoking at initiation of treatment and who are regular and constant smokers.




Read More
Fact Sheet

Nicotine Nasal Spray (Nicotrol NS) Fact Sheet

January 1, 2026
Daniel Carlat, MD and Talia Puzantian, PharmD, BCPP

Dr. Puzantian and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

The idea of nasal administration of nicotine is appealing in that it more closely approximates the time course of plasma nicotine levels observed after cigarette smoking than other dosage forms; however, the high cost and unpleasant side effects make this difficult to recommend as a first-line treatment, especially since no one form of nicotine replacement therapy has been shown to be more effective than another.




Read More
Fact Sheet

Nicotine Inhaled (Nicotrol Inhaler) Fact Sheet

January 1, 2026
Daniel Carlat, MD and Talia Puzantian, PharmD, BCPP

Dr. Puzantian and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Inhaled nicotine is expensive and can cause unpleasant side effects, both of which make this form of nicotine replacement therapy difficult to recommend as a first-line option since no single therapy has been shown to be more effective than another.




Read More
Fact Sheet

Nicotine Gum/Lozenge (Nicorette, others) Fact Sheet

January 1, 2026
Daniel Carlat, MD and Talia Puzantian, PharmD, BCPP

Dr. Puzantian and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

First-line intervention for those patients who can stop smoking at initiation of therapy; nicotine in the form of gum or lozenge may act as a substitute oral activity, which may aid in behavior modification.




Read More
Fact Sheet

Bupropion SR (Zyban) Fact Sheet

January 1, 2026
Daniel Carlat, MD and Talia Puzantian, PharmD, BCPP

Dr. Puzantian and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

DSM-5: “Problematic pattern” of tobacco use leading to “significant distress” that lasts at least 12 months.




Read More
Fact Sheet

Smoking Cessation

January 1, 2026
Daniel Carlat, MD and Talia Puzantian, PharmD, BCPP

Dr. Puzantian and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

DSM-5: “Problematic pattern” of tobacco use leading to “significant distress” that lasts at least 12 months.




Read More
Previous 1 2 … 6 7 8 9 10 11 12 13 14 … 56 57 Next
Try The New AskCarlat AI

Ask any clinical question—our AI responds using only the peer-reviewed, editorially vetted content from Carlat Publishing.

Available In The Carlat Toolkit
Free Psychiatry Updates
The latest unbiased psychiatric information sent to your inbox.
Specify Your Interests
Featured Book
  • MFB8e_SpiralCover.png

    Medication Fact Book for Psychiatric Practice, Eighth Edition (2026)

    Updated 2026 prescriber's guide.
    READ MORE
Featured Video
  • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
    General Psychiatry

    KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

    Read More
Featured Podcast
  • shutterstock_2782224449.jpg
    General Psychiatry

    Gender Affirming Care: Fall of the House of Hopkins

    Listen now
Recommended
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report
  • The Carlat Psychotherapy Report

Contact

carlat@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2026 Carlat Publishing, LLC and Affiliates, All Rights Reserved.